Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,570

Employees7,570

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,570

Employees7,570

BIIB Key Statistics

Market cap

30.44B

Market cap30.44B

Price-Earnings ratio

26.09

Price-Earnings ratio26.09

Dividend yield

—

Dividend yield—

Average volume

1.58M

Average volume1.58M

High today

$210.82

High today$210.82

Low today

$199.10

Low today$199.10

Open price

$201.22

Open price$201.22

Volume

1.88M

Volume1.88M

52 Week high

$319.76

52 Week high$319.76

52 Week low

$189.44

52 Week low$189.44

BIIB News

Simply Wall St 2h

Earnings Update: Biogen Inc. Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St

It's been a good week for Biogen Inc. ( ) shareholders, because the company has just released its latest first-quarter results, and the shares gained 7.5% to US...

Simply Wall St 4h

Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biogen (NASDAQ:BIIB) First Quarter 2024 Results Key Financial Results Revenue: US$2.29b (down 7.0% from 1Q 2023). Net income: US$393.4m (up 1.4% from 1Q 2023...

Simply Wall St 1d

Biogen Inc. Just Released Its First-Quarter Earnings: Here's What Analysts Think

It's been a good week for Biogen Inc. (NASDAQ:BIIB) shareholders, because the company has just released its latest first-quarter results, and the shares gained...

Analyst ratings

74%

of 35 ratings

Buy

74.3%

Hold

25.7%

Sell

More BIIB News

Yahoo Finance 2d

Sage Therapeutics Q1 Earnings Miss, Sales Beat Estimates - Yahoo Finance

Sage Therapeutics SAGE reported a loss of $1.80 per share in the first quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.63. The company...

TipRanks 2d

Sage Therapeutics price target lowered to $15 from $26 at RBC Capital

RBC Capital lowered the firm’s price target on Sage Therapeutics (SAGE) to $15 from $26 and keeps a Sector Perform rating on the shares after its Q1 earnings mi...

Quartz 2d

Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup

A new report from Morgan Stanley finds that people using GLP-1 drugs — among them Ozempic, Wegovy, Mounjaro, and Zepbound — reduce their consumption of tobacco...

Yahoo Finance 3d

Decoding Biogen Inc: A Strategic SWOT Insight - Yahoo Finance

Biogen Inc's robust product portfolio and pipeline offer a competitive edge in the neurology and immunology sectors. Despite a slight revenue dip, Biogen maint...

TipRanks 3d

Biogen announces CHMP opinion recommending Tofidence

Biogen announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted an opinion for Tofidence, a...

Yahoo Finance 3d

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX - Yahoo Finance

It was a busy week in the biotech sector with earnings reports from bigwigs Biogen BIIB and Bristol Myers Squibb BMY. Other regulatory and acquisition updates w...

Quartz 3d

Drug sales keep beating Wall Street's expectations and boosting some pharma stocks

It has been a busy week for pharma giants reporting their latest quarterly earnings and a lot of them have exceeded analysts’ estimates. HGTV's Property Brot...